Boniva is a brand name of ibandronate, approved by the FDA in the following formulation(s):
BONIVA (ibandronate sodium - injectable; intravenous)
Manufacturer: ROCHE
Approval date: January 6, 2006
Strength(s): EQ 3MG BASE/3ML [RLD]
BONIVA (ibandronate sodium - tablet; oral)
Manufacturer: ROCHE
Approval date: March 24, 2005
Strength(s): EQ 150MG BASE [RLD]
Has a generic version of Boniva been approved?
No. There is currently no therapeutically equivalent version of Boniva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Boniva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Diphosphonate derivatives, pharmaceutical compositions and methods of use
Patent 4,927,814
Issued: May 22, 1990
Inventor(s): Gall; Rudi & Bosies; Elmar
Assignee(s): Boehringer Mannheim GmbH
The present invention provides disphosphonates of the general formula: ##STR1## wherein R.sub.1 is a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical of 1-9 carbon atoms which is optionally substituted by phenyl or cyclohexyl, R.sub.2 is cyclohexyl or cyclohexylmethyl, benzyl or a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon of 4 to 18 carbon atoms which is optionally substituted by phenyl or oxygen wherein the oxygen can be esterified or etherified, R.sub.3 is hydrogen or a straight-chain or branched alkyl of 1-4 carbon atoms, X is a straight-chain or branched alkylene chain of 1-6 carbon atoms and Y is hydrogen, hydroxyl or an amino group optionally substituted by alkyl radicals of 1-6 carbon atoms; as well as the pharmacologically acceptable salts thereof. The present invention also provides processes for the preparation of these diphosphonic acid derivatives and pharmaceutical compositions containing them for the prophyllaxis treatment of diseases or disturbances of calcium metabolism such as osteoporsis, Pagets disease, Bechterew's disease, bone metastases, urolithiasis, heterotropic ossifications, rheumatoid arthritis, osteoarthritis and degenerative arthrosis.Patent expiration dates:
- March 17, 2012✓✓✓
- March 17, 2012✓✓✓
- March 17, 2012
Pharmaceutical agents containing diphosphonic acids and salts thereof
Patent 5,662,918
Issued: September 2, 1997
Inventor(s): Winter; Gerhard & Pichler; Bernhard & Woog; Heinrich & Heller; Werner
Assignee(s): Boehringer Mannheim GmbH
The invention concerns pharmaceutical preparations that are stable on storage, which contain at least one diphosphonic acid and/or at least one physiologically acceptable salt of such an acid as the active substance.Patent expiration dates:
- September 2, 2014✓
- September 2, 2014
Oral pharmaceutical preparation containing ibandronat
Patent 6,143,326
Issued: November 7, 2000
Inventor(s): Mockel; Jorn & Gabel; Rolf-Dieter & Woog; Heinrich
Assignee(s): Roche Diagnostics GmbH
The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.Patent expiration dates:
- April 21, 2017✓
- April 21, 2017
Pharmaceutical composition containing diphosphonic acid or salt thereof
Patent 6,294,196
Issued: September 25, 2001
Inventor(s): Gabel; Rolf-Dieter & Preis; Walter & Woog; Heinrich
Assignee(s): Hoffmann-La Roche Inc.
The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.Patent expiration dates:
- October 7, 2019✓
- October 7, 2019
Method of treatment using bisphosphonic acid
Patent 7,192,938
Issued: March 20, 2007
Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
Assignee(s): Hoffmann-La Roche Inc.
The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Patent expiration dates:
- May 6, 2023✓
- May 6, 2023
Method of treatment using bisphosphonic acid
Patent 7,410,957
Issued: August 12, 2008
Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
Assignee(s): Hoffmann-La Roche Inc.
The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Patent expiration dates:
- May 6, 2023✓
- May 6, 2023
Method of treatment using bisphosphonic acid
Patent 7,718,634
Issued: May 18, 2010
Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
Assignee(s): Hoffman-La Roche Inc.
The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Patent expiration dates:
- May 6, 2023✓
- May 6, 2023
See also...
- Boniva Consumer Information (Drugs.com)
- Boniva Consumer Information (Drugs.com)
- Boniva Consumer Information (Wolters Kluwer)
- Boniva Consumer Information (Cerner Multum)
- Boniva Advanced Consumer Information (Micromedex)
- Boniva Intravenous Advanced Consumer Information (Micromedex)
- Boniva AHFS DI Monographs (ASHP)
- Boniva IV Injection Consumer Information (Drugs.com)
- Ibandronate Consumer Information (Wolters Kluwer)
- Ibandronate Consumer Information (Cerner Multum)
- Bondronat Advanced Consumer Information (Micromedex)
- Ibandronate Intravenous Advanced Consumer Information (Micromedex)
- Ibandronate Oral, Injection Advanced Consumer Information (Micromedex)
- Ibandronate Sodium AHFS DI Monographs (ASHP)
No comments:
Post a Comment